Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2024-02-01 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
PFA letter comprising details of loss of share certificates.
Regulatory Filings
2024-02-01 English
Loss of Share Certificates
Regulatory Filings
2024-02-01 English
Please find attached copy of newspaper publication of Q-3 FY 2024 Results.
Regulatory Filings
2024-02-01 English
Copy of Newspaper Publication
Regulatory Filings
2024-02-01 English
Updates
Board/Management Information Classification · 100% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board of Directors meeting. It specifically announces the appointment of a senior management personnel, Mr. Vikas Sharma, including his profile and appointment date. The document references compliance with SEBI (LODR) Regulations and a SEBI circular, indicating it is a regulatory announcement. The content focuses on management changes rather than financial results, reports, or other filings. The document length is under 5,000 characters and does not contain financial data or detailed reports, so it is not an Annual Report, Interim Report, or similar. It is not a report publication announcement but a direct announcement of a management appointment. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-02-01 English
Please find attached details.
Board/Management Information Classification · 100% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board of Directors meeting. It specifically announces the appointment of a senior management personnel, Mr. Vikas Sharma, including his profile and appointment date. The document references compliance with SEBI (LODR) Regulations and a SEBI circular, indicating it is a regulatory announcement. The content focuses on management changes rather than financial results, reports, or presentations. The document length is under 5,000 characters and does not contain financial data or detailed reports, so it is not an Annual Report, Interim Report, or similar. It is not a voting result, dividend notice, or legal proceeding. The key content is the announcement of a change in senior management personnel, which fits the category of Board/Management Information (MANG).
2024-02-01 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.